UPLC/Q‑TOF‑MS based plasma metabolomics and clinical characteristics of polycystic ovarian syndrome

Fan,Xuemei; Jiang,Jianfa; Huang,Zhiqiang; Gong,Jumei; Wang,Yiming; Xue,Wei; Deng,Yan; Wang,Yanfang; Zheng,Tingping; Sun,Aijun; Luo,Guoan

doi:10.3892/mmr.2018.9643

UPLC/Q‑TOF‑MS based plasma metabolomics and clinical characteristics of polycystic ovarian syndrome

Authors:
- Xuemei Fan
- Jianfa Jiang
- Zhiqiang Huang
- Jumei Gong
- Yiming Wang
- Wei Xue
- Yan Deng
- Yanfang Wang
- Tingping Zheng
- Aijun Sun
- Guoan Luo
View Affiliations

Affiliations: Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology (Ministry of Education), Department of Chemistry, Tsinghua University, Beijing 100084, P.R. China, Department of Obstetrics and Gynecology, Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, P.R. China, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, P.R. China
Published online on: November 12, 2018 https://doi.org/10.3892/mmr.2018.9643
Pages: 280-292
Copyright: © Fan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to develop novel diagnostic methods for polycystic ovarian syndrome (PCOS) by screening and identifying specific PCOS‑associated metabolic markers using plasma metabolomics. Ultra‑performance liquid chromatography/quadrapole‑time of flight‑mass spectrometry was adopted to establish the plasma metabolic fingerprint of 49 patients and 50 normal controls, in order to screen the potential metabolic markers. In addition, these markers were integrated with the clinical indexes, followed by focused analysis to obtain diagnostic markers. The present results demonstrated that not only was the concentration of palmitoyl sphingomyelin in plasma of patients with PCOS significantly increased; however, a statistically significant difference between the two PCOS subgroups was additionally demonstrated. At the same time, the concentrations of cyclic guanosine monophosphate (cGMP) and dehydroepiandrosterone sulphate in the plasma of patients of the subgroup 1 were significantly elevated. These markers were additionally integrated with the clinical index number of follicles in the left ovary and high‑density lipoprotein (HDL‑C), followed by receiver operating characteristic curve analysis, which demonstrated a diagnostic accuracy of ~90% in the control and the two subgroups. The integrated marker system consisting of palmitoyl sphingomyelin, cGMP and androsterone sulfate, as well as the number of left follicles and HDL‑C may be used for the accurate diagnosis and classification of PCOS. These results confirmed that the abnormalities in hormone metabolism and lipid metabolism disorder were primarily involved in the onset of PCOS.

View Figures

View References

1	Glintborg D and Andersen M: An update on the pathogenesis, inflammation, and metabolism in hirsutism and polycystic ovarysyndrome. Gynecol Endocrinol. 26:281–296. 2010. View Article : Google Scholar : PubMed/NCBI
2	Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, et al: Positions statement: Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: An androgen excess society guideline. J Clin Endocrinol Metab. 91:4237–4245. 2006. View Article : Google Scholar : PubMed/NCBI
3	Knebel B, Janssen OE, Hahn S, Jacob S, Gleich J, Kotzka J and Muller-Wieland D: Increased low grade inflammatory serum markers in patients with polycystic ovary syndrome (PCOS) and their relationship to PPARgamma gene variants. Exp Clin Endocrinol Diabet. 116:481–486. 2008. View Article : Google Scholar
4	Lerchbaum E, Schwetz V, Giuliani A and Obermayer-Pietsch B: Influence of a positive family history of both type 2 diabetes and PCOS on metabolic and endocrine parameters in a large cohort of PCOS women. Eur J Endocrinol. 170:727–739. 2014. View Article : Google Scholar : PubMed/NCBI
5	Zhao S, Tian Y, Gao X, Zhang X, Liu H, You L, Cao Y, Su S, Chan WY, Sun Y, et al: Family-based analysis of eight susceptibility loci in polycystic ovary syndrome. Sci Rep. 5:126192015. View Article : Google Scholar : PubMed/NCBI
6	Kume T, Calan M, Yilmaz O, Kocabas GU, Yesil P, Temur M, Bicer M and Calan OG: A possible connection between tumor necrosis factor alpha and adropin levels in polycystic ovary syndrome. J Endocrinol Invest. 39:747–754. 2016. View Article : Google Scholar : PubMed/NCBI
7	Chen YX, Zhang XZ, Huang J, Zhou SJ, Liu F, Jiang LL, Chen M, Wan JB and Yang DZ: UHPLC/Q-TOFMS-based plasma metabolomics of polycystic ovary syndrome patients with and without insulin resistance. J Pharm Biomed Anal. 121:141–150. 2016. View Article : Google Scholar : PubMed/NCBI
8	Zhao Y, Fu L, Li R, Wang LN, Yang Y, Liu NN, Zhang CM, Wang Y, Liu P, Tu BB, et al: Metabolic profiles characterizing different phenotypes of polycystic ovary syndrome: Plasma metabolomics analysis. BMC Med. 10:1532012. View Article : Google Scholar : PubMed/NCBI
9	Rautio K, Tapanainen JS, Ruokonen A and Morin-Papunen LC: Rosiglitazon treatment alleviates inflammation and improves liver function in overweight women with polycystic ovary syndrome: A randomized placebo controlled study. Fertil Steril. 87:202–226. 2007. View Article : Google Scholar : PubMed/NCBI
10	Baskind NE and Balen AH: Hypothalamic-pituitary, ovarian and adrenal contributions to polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 37:80–97. 2016. View Article : Google Scholar : PubMed/NCBI
11	Lian Y, Zhao F and Wang W: Central leptin resistance and hypothalamic inflammation are involved in letrozole-induced polycystic ovary syndrome rats. Biochem Biophys Res Commun. 476:306–312. 2016. View Article : Google Scholar : PubMed/NCBI
12	Cheng F, Zhao L, Wu Y, Huang T, Yang G, Zhang Z, Wu Y, Jia F, Wu J, Chen C and Liu D: Serum vascular endothelial growth factor B is elevated in women with polycystic ovary syndrome and can be decreased with metformin treatment. Clin Endocrinol (Oxf). 84:386–393. 2016. View Article : Google Scholar : PubMed/NCBI
13	Atiomo W and Daykin CA: Metabolomic biomarkers in women with polycystic ovary syndrome: A pilot study. Mol Hum Reprod. 18:546–553. 2012. View Article : Google Scholar : PubMed/NCBI
14	Sun LY, Hu WH, Liu Q, Hao Q, Sun B, Zhang Q, Mao S, Qiao J and Yan X: Metabonomics reveals plasma metabolic changes and inflammatory marker in polycystic ovary syndrome patients. J Proteome Res. 11:2937–2946. 2012. View Article : Google Scholar : PubMed/NCBI
15	Zhao XJ, Xu F, Qi B, Hao S, Li Y, Li Y, Zou L, Lu C, Xu G and Hou L: Serum metabolomics study of polycystic ovary syndrome based on liquid chromatography-mass spectrometry. J Proteome Res. 13:1101–1111. 2014. View Article : Google Scholar : PubMed/NCBI
16	Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 81:19–25. 2004. View Article : Google Scholar
17	Lujan ME, Chizen DR and Pierson RA: Diagnostic criteria for polycystic ovary syndrome: Pitfalls and controversies. J Obstet Gynaecol Can. 30:671–679. 2008. View Article : Google Scholar : PubMed/NCBI
18	Xue YJ, Xie H, Sun ML, et al: Characteristics of abnormal lipid metabolism in PCOS patients with insulin resistance. Chin J Mod Med. 24:94–98. 2014.(In Chinese).
19	Yilmaz M, Biri A, Bukan N, Karakoç A, Sancak B, Törüner F and Paşaoğlu H: Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome. Gynecol Endocrinol. 20:258–263. 2005. View Article : Google Scholar : PubMed/NCBI
20	Padmapriya B and Kesavamurthy T: Detection of follicles in poly cystic ovarian syndrome in ultrasound images using morphological operations. J Med Imaging Health Inform. 6:240–243. 2016. View Article : Google Scholar
21	Walch K, Grimm C, Zeillinger R, Huber JC, Nagele F and Hefler LA: A common interleukin-6 gene promoter polymorphism influences the clinical characteristicsof women with polycystic ovary syndrome. Fertil Steril. 81:1638–1641. 2004. View Article : Google Scholar : PubMed/NCBI
22	Vgontzas AN, Trakada G, Bixler EO, Lin HM, Pejovic S, Zoumakis E, Chrousos GP and Legro RS: Plasma interleukin 6 levels are elevated in polycystic ovary syndrome independently ofobesity or sleep apnea. Metabolism. 55:1076–1082. 2006. View Article : Google Scholar : PubMed/NCBI
23	Verit FF: High sensitive serum C-reactive protein and its relation-ship with other cardiovascular risk factors in normoinsulinemic polycystic ovary patients without metabolic syndrome. Arch Gynecol Obstet. 281:1009–1014. 2010. View Article : Google Scholar : PubMed/NCBI
24	Dong F, Deng D, Chen H, Cheng W, Li Q, Luo R and Ding S: Serum metabolomics study of polycystic ovary syndrome based on UPLC-QTOF-MS coupled with a pattern recognition approach. Anal Bioanal Chem. 407:4683–4695. 2015. View Article : Google Scholar : PubMed/NCBI
25	Martina V, Benso A, Gigliardi VR, Masha A, Origlia C, Granata R and Ghigo E: Short-term dehydroepiandrosterone treatment increases platelet cGMP production in elderly male subjects. Clin Endocrinol (Oxf). 64:260–264. 2006. View Article : Google Scholar : PubMed/NCBI
26	Martina V, Origlia C, Bruno GA, Messina M, Ferri M and Pescarmona GP: Serum DHEAS levels correlate with platelet cGMP in normal women. J Endocrinol Invest. 24:RC28–RC30. 2001. View Article : Google Scholar : PubMed/NCBI
27	Holte J, Bergh T, Gennarelli G and Wide L: The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women. Clin Endocrinol (Oxf). 41:473–481. 1994. View Article : Google Scholar : PubMed/NCBI
28	Huang A, Brennan K and Azziz R: Prevalence of hyperandrogenemia in the polycystic ovary syndrome diagnosed by the National Institutes of Health 1990 criteria. Fertil Steril. 93:1938–1941. 2010. View Article : Google Scholar : PubMed/NCBI